AlphaMark Advisors LLC Buys 514 Shares of Bristol-Myers Squibb (NYSE:BMY)

AlphaMark Advisors LLC boosted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 2.3% during the 1st quarter, HoldingsChannel reports. The fund owned 22,605 shares of the biopharmaceutical company’s stock after buying an additional 514 shares during the quarter. AlphaMark Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,226,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in BMY. Northwest Financial Advisors bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $27,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at $34,000. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $40,000. Wetzel Investment Advisors Inc. bought a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $40,000. Finally, Fairman Group LLC acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $42,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 0.6 %

BMY stock traded down $0.23 during midday trading on Monday, reaching $41.30. The stock had a trading volume of 14,627,903 shares, compared to its average volume of 15,763,631. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a twelve month low of $39.63 and a twelve month high of $65.38. The firm has a market cap of $83.72 billion, a price-to-earnings ratio of -13.32, a PEG ratio of 14.21 and a beta of 0.44. The business has a fifty day simple moving average of $42.97 and a two-hundred day simple moving average of $48.11.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the previous year, the firm posted $2.05 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% compared to the same quarter last year. As a group, research analysts expect that Bristol-Myers Squibb will post 0.58 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.81%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Analysts Set New Price Targets

BMY has been the subject of a number of analyst reports. Barclays cut their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. Finally, Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.